| VRSK |
Report |
Revenue |
IN-LINE |
pred ~$806M vs. cons $804.5M |
LOW |
| VRSK |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$1.94 vs. cons $1.926 |
LOW |
| VRSK |
Report |
OCC revenue growth |
MISS |
pred ~5.1% vs. cons 5.35% |
LOW |
| VRSK |
Guide |
FY2026 revenue |
UNCHANGED |
guide ~$3.19B-$3.24B vs. cons $3.223B |
LOW |
| VRSK |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$7.45-$7.75 vs. cons $7.673 |
LOW |
| VRSK |
Guide |
Q3/H2 OCC recovery commentary |
BETTER |
guide ~recovery toward 6%-8% vs. Q3 cons 5.35% |
LOW |
| VRSK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
LOW |
| VRSK |
Return |
5-day cumulative residual |
-4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — modest H2 de-risking |
LOW |